Baricitinib in rheumatoid arthritis-interstitial lung disease: a literature review and national multicentre study of 72 patients
Authors' conclusion
BARI may be a useful and safe alternative in both pulmonary and joint disease in RA-ILD patients, even in refractory cases.
Study context
- Population
- RA-ILD patients treated with baricitinib in clinical practice (52 women; mean age 68 years); all had received DMARDs52 women
- Participants
- 72 patients
- Outcome
- Effectiveness (dyspnea, FVC, DLCO, chest HRCT, DAS28-ESR, CS-sparing effect) and safety of baricitinib (BARI) in RA-ILD
- Follow-up
- 3, 6, 12, 18 and 24 months, and last
Methodological detailsnational multicentre, literature review up to December 2023
- National multicentre
- Literature review up to December 2023
Main finding
As reported in the abstract
Pulmonary outcomes improved or stabilized · median [IQR] follow-up 32 [13-65] months
Dyspnea improved or stabilized
90%
Forced vital capacity (FVC) improved or stabilized
88%
DLCO improved or stabilized
65%
High-resolution CT (HRCT) improved or stabilized
72%
Observational data: associations, not effects.
Further findings
Arthritis activity (DAS28-ESR), mean
- Mean DAS28-ESR improved from 4.29 to 2.99
CS-sparing effect: median prednisone dose
- Median prednisone dose reduced from 5 to 2.5 mg/day
Original publication
Baricitinib in rheumatoid arthritis-interstitial lung disease: a literature review and national multicentre study of 72 patients. Rheumatology (Oxford). Published 10 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →